Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 125Breast 9Thoracic 7Gastrointestinal 7Tumor-Agnostic 4Head & Neck 3Gynecologic 3Dermatologic 3Sarcoma 1Other solid neoplasm 1Lymphoid 1

Conditions

Solid Tumor 1

Interventions

pembrolizumab 75Injections 67Carboplatin 38Pemetrexed 29Cisplatin 29Nivolumab 27Specimen Handling 24Interviews as Topic 24Cyclophosphamide 24atezolizumab 21tislelizumab 20Bevacizumab 20Paclitaxel 19Standard of Care 16Practice Guidelines as Topic 16fludarabine 15Docetaxel 15toripalimab 14Ipilimumab 14Educational Status 14Cetuximab 14Fluorouracil 13Oxaliplatin 12Etoposide 12olaparib 11durvalumab 11Methods 11Gemcitabine 11Early Intervention, Educational 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
enzalutamide × Other solid neoplasm × 1 year × Clear all
NCT06576037 2026-04-16

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

M.D. Anderson Cancer Center

Phase 1 Recruiting
128 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡